Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of VH4770359 in Healthy Participants
NCT07525544Phase 1Recruiting
- Sponsor
- ViiV Healthcare
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VH4770359 in human immunodeficiency virus infection (HIV) (6 arms), sponsored by ViiV Healthcare. Primary endpoint: Number of participants with Grade 3 and Grade 4 adverse events at 9 weeks. Started May 2026; status: recruiting.
02
Drugs
VH4770359
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07525544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07525544.